Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
The Hidden Impurity in Compounded Tirzepatide: What Lilly's Lab Found in Your B12 Combo
Eli Lilly's analytical labs discovered a novel chemical impurity in compounded tirzepatide-B12 products—a compound formed by a reaction between the two ingredients that nobody has tested for safety.
What’s Actually in Your Peptide Vial? The Testing Data Is Alarming
Independent labs are testing 7,000 peptide samples a month. One-third fail basic quality checks. A Belgian study found arsenic in every sample tested. Here’s what the data shows.
FDA PCAC July 2026: The 7 Peptides That Could Return to Legal Compounding
The FDA scheduled a July advisory committee meeting to review BPC-157, TB-500, and five other peptides for potential return to legal compounding. Here's what the meeting actually means—and what it doesn't.
FDA Removes 12 Peptides from Restricted List — Compounding Access Could Return by July 2026
The FDA has removed 12 peptides from its restricted Category 2 list and scheduled PCAC meetings for July 2026. BPC-157, TB-500, KPV, and 9 others could become legally available for compounding again.
The Oral GLP-1 Revolution: How Foundayo Bests Injectable Semaglutide
Foundayo (orforglipron) outperforms injectable semaglutide in head-to-head Phase 3 trials, offering superior A1C reduction and weight loss as an oral small-molecule GLP-1 RA.
The FDA Is Reviewing 12 Peptides. Here's What That Actually Means.
After two years of restrictions, the FDA is provisionally removing 12 peptides from its banned list and scheduling formal reviews. Which ones are back, what the science says, and what patients should know right now.